Drug Overview
Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants.
Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.
Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants.
Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.
Table of Contents
OVERVIEW- Drug Overview
- Product Profiles
- Trumenba : Meningococcal vaccines
LIST OF TABLES
Table 1: Trumenba drug profile
Table 2: Approval history of Trumenba for meningococcal vaccination in the US and five major EU markets
Table 3: Late-phase trials of Trumenba for meningococcal vaccination
Table 4: Trumenba for meningococcal disease – SWOT analysis
